India, Nov. 9 -- The U.S. Food and Drug Administration (FDA) has required safety labeling updates for GLP-1 medicines used to treat diabetes and obesity, citing a potential increased risk of a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).
GLP-1 drugs include widely used treatments such as Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and several others. These medicines are prescribed for conditions including type 2 diabetes, obesity and certain cardiovascular and kidney-related diseases.
NAION is a rare condition that can cause sudden, painless vision loss in one eye, with the potential for permanent damage. The FDA said manufacturers must add information about the potential risk to the W...